Which conditions is Abciximab approved to treat as an adjunct therapy?

Abciximab is an antiplatelet agent primarily used as an adjunct therapy in the context of percutaneous coronary intervention (PCI) and in patients with unstable angina who are unresponsive to standard treatments. Its function is to inhibit platelet aggregation, thereby preventing thrombosis during and after PCI procedures, which is essential for improving outcomes by reducing the risk of complications associated with these procedures.

In the case of PCI, Abciximab helps to enhance the effectiveness of the intervention by ensuring that platelets do not aggregate and form clots that could obstruct the coronary arteries. For patients with unstable angina who do not respond well to other drugs, Abciximab provides critical support in managing their condition, reducing the chances of progression to a myocardial infarction (heart attack).

Other choices are not applicable as primary indications for Abciximab. It is not indicated for heart failure, stroke, peripheral vascular disease, hypertension, or arrhythmias, reflecting its specific role in managing conditions related to acute coronary syndromes and interventions that affect coronary circulation. This specificity makes the selection of PCI and unresponsive unstable angina the correct context for Abciximab’s usage as an adjunct therapy.